CN121910740A - 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法 - Google Patents

用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法

Info

Publication number
CN121910740A
CN121910740A CN202511504739.0A CN202511504739A CN121910740A CN 121910740 A CN121910740 A CN 121910740A CN 202511504739 A CN202511504739 A CN 202511504739A CN 121910740 A CN121910740 A CN 121910740A
Authority
CN
China
Prior art keywords
atp channel
formulation
channel opener
obese
growth hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511504739.0A
Other languages
English (en)
Chinese (zh)
Inventor
N·M·考恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Solano Treatment Co
Original Assignee
Solano Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solano Treatment Co filed Critical Solano Treatment Co
Publication of CN121910740A publication Critical patent/CN121910740A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202511504739.0A 2014-11-14 2015-11-12 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法 Pending CN121910740A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201462080150P 2014-11-14 2014-11-14
US62/080,150 2014-11-14
US201562138245P 2015-03-25 2015-03-25
US62/138,245 2015-03-25
US201562170035P 2015-06-02 2015-06-02
US62/170,035 2015-06-02
US201562221359P 2015-09-21 2015-09-21
US62/221,359 2015-09-21
CN201580072525.9A CN107106500B (zh) 2014-11-14 2015-11-12 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法
PCT/US2015/060455 WO2016077629A1 (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580072525.9A Division CN107106500B (zh) 2014-11-14 2015-11-12 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法

Publications (1)

Publication Number Publication Date
CN121910740A true CN121910740A (zh) 2026-04-24

Family

ID=55955075

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202511504739.0A Pending CN121910740A (zh) 2014-11-14 2015-11-12 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法
CN201580072525.9A Active CN107106500B (zh) 2014-11-14 2015-11-12 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法
CN202110786768.6A Active CN113599386B (zh) 2014-11-14 2015-11-12 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201580072525.9A Active CN107106500B (zh) 2014-11-14 2015-11-12 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法
CN202110786768.6A Active CN113599386B (zh) 2014-11-14 2015-11-12 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法

Country Status (19)

Country Link
US (8) US10058557B2 (https=)
EP (1) EP3217963B1 (https=)
JP (4) JP6709226B2 (https=)
KR (4) KR102323613B1 (https=)
CN (3) CN121910740A (https=)
AU (2) AU2015346196B2 (https=)
BR (1) BR112017009986A2 (https=)
CA (4) CA3125839C (https=)
DK (1) DK3217963T3 (https=)
EA (1) EA036103B1 (https=)
ES (1) ES2806977T3 (https=)
HU (1) HUE050895T2 (https=)
IL (1) IL252111B (https=)
MX (2) MX381305B (https=)
MY (1) MY187610A (https=)
NZ (1) NZ768958A (https=)
PL (1) PL3217963T3 (https=)
SG (1) SG11201703721SA (https=)
WO (1) WO2016077629A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781265B1 (en) 2004-08-25 2010-04-07 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
EP2404604B1 (en) 2006-01-05 2019-02-06 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
KR102323613B1 (ko) 2014-11-14 2021-11-09 에센셜리스 인코포레이티드 프라더-윌리 증후군 또는 스미스-마제니스 증후군을 가지는 대상체를 치료하는 방법
AU2017275652B2 (en) * 2016-06-03 2023-02-16 Levo Therapeutics, Inc. Methods of treating Prader-Willi syndrome
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
TW202031283A (zh) * 2018-09-20 2020-09-01 馬克 Ｃ 曼寧 穩定卡貝縮宮素鼻內製劑
CN111888330B (zh) * 2020-09-18 2022-08-16 常州市第四制药厂有限公司 一种二氮嗪口服混悬溶液及制备方法
CN120530097A (zh) * 2022-10-18 2025-08-22 节奏制药公司 新颖的atp敏感性钾通道增效剂、其制备和用途
WO2025057119A1 (en) * 2023-09-15 2025-03-20 Soleno Therapeutics, Inc. Methods of managing glycemic control in prader-willi syndrome patients
WO2025222188A1 (en) * 2024-04-18 2025-10-23 Rhythm Pharmaceuticals, Inc. Novel potassium channel opener compounds and related uses

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2986573A (en) 1961-01-18 1961-05-30 Schering Corp Method for the treatment of hypertension
GB8601204D0 (en) 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US5284845A (en) 1991-03-14 1994-02-08 Paulsen Elsa P Use of oral diazoxide for the treatment of disorders in glucose metabolism
US5629045A (en) 1992-09-17 1997-05-13 Richard L. Veech Biodegradable nosiogenic agents for control of non-vertebrate pests
US5399359A (en) 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US6225310B1 (en) * 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
AU4133997A (en) 1996-09-12 1998-04-02 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
US6197765B1 (en) 1999-06-08 2001-03-06 Pnina Vardi Use of diazoxide for the treatment of metabolic syndrome and diabetes complications
WO2002000223A1 (en) 2000-06-26 2002-01-03 Novo Nordisk A/S Use of potassium channel agonists for reducing fat food comsumption
TW478039B (en) 2001-04-09 2002-03-01 Promos Technologies Inc Phase shift alignment system
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6960346B2 (en) 2002-05-09 2005-11-01 University Of Tennessee Research Foundation Vehicles for delivery of biologically active substances
US20040143213A1 (en) 2002-11-12 2004-07-22 Collegium Pharmaceutical, Inc. Inertial drug delivery system
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
CA2571717A1 (en) * 2004-06-23 2006-01-05 Josette-Nicole Mahy Gehenne Compounds for the treatment of inflammation of the central nervous system
CN101043879A (zh) * 2004-08-25 2007-09-26 伊森舍丽斯有限公司 钾atp通道开放剂的药物制剂及其应用
EP1781265B1 (en) 2004-08-25 2010-04-07 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
AU2005298692A1 (en) * 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
CN101257897A (zh) * 2005-07-07 2008-09-03 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
EP2404604B1 (en) 2006-01-05 2019-02-06 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US20070293552A1 (en) * 2006-06-15 2007-12-20 Gorczynski Richard J Antihypertensive therapy method
EP2170341A4 (en) 2007-07-02 2010-12-01 Essentialis Inc SALTS OF KALIUM ATP CHANNEL OPENERS AND ITS USES
US20120238554A1 (en) 2007-07-02 2012-09-20 Cowen Neil M Salts of potassium atp channel openers and uses thereof
EP2395987A1 (en) * 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
HRP20190062T1 (hr) * 2011-12-15 2019-03-08 Millendo Therapeutics Sas Fragmenti neaciliranog grelina za uporabu u liječenju prader-willi sindroma
EP2819675A4 (en) 2012-02-27 2015-07-22 Essentialis Inc SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF
JP2014074004A (ja) * 2012-10-05 2014-04-24 Shinichi Niijima 精神症状の改善剤
WO2014197753A1 (en) 2013-06-08 2014-12-11 Sedogen, Llc Method of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia
KR102323613B1 (ko) 2014-11-14 2021-11-09 에센셜리스 인코포레이티드 프라더-윌리 증후군 또는 스미스-마제니스 증후군을 가지는 대상체를 치료하는 방법

Also Published As

Publication number Publication date
EP3217963A4 (en) 2018-07-04
KR20230049760A (ko) 2023-04-13
CA2966907A1 (en) 2016-05-19
CN113599386A (zh) 2021-11-05
US20240207284A1 (en) 2024-06-27
CA3125835C (en) 2023-01-03
CN113599386B (zh) 2025-12-05
KR102452254B1 (ko) 2022-10-11
JP7232300B2 (ja) 2023-03-02
HK1243954A1 (en) 2018-07-27
IL252111A0 (en) 2017-07-31
DK3217963T3 (da) 2020-07-20
BR112017009986A2 (pt) 2018-02-14
CA3125835A1 (en) 2016-05-19
NZ731565A (en) 2021-06-25
KR102517840B1 (ko) 2023-04-05
US20200147100A1 (en) 2020-05-14
KR20170082625A (ko) 2017-07-14
EP3217963A1 (en) 2017-09-20
US20210322434A1 (en) 2021-10-21
MX2017006244A (es) 2018-02-26
JP6955039B2 (ja) 2021-10-27
KR20220124289A (ko) 2022-09-13
KR102323613B1 (ko) 2021-11-09
US20180021344A1 (en) 2018-01-25
MX381305B (es) 2025-03-12
CA3125839A1 (en) 2016-05-19
US10456408B2 (en) 2019-10-29
CA3125839C (en) 2023-10-24
JP2020073566A (ja) 2020-05-14
CN107106500B (zh) 2021-07-30
PL3217963T3 (pl) 2020-10-19
US12109216B2 (en) 2024-10-08
US20190105327A1 (en) 2019-04-11
US12343348B2 (en) 2025-07-01
AU2019202906B2 (en) 2020-05-21
EP3217963B1 (en) 2020-05-20
SG11201703721SA (en) 2017-06-29
KR20210134843A (ko) 2021-11-10
US10874676B2 (en) 2020-12-29
CA2966907C (en) 2021-09-07
US20250120979A1 (en) 2025-04-17
JP2023056025A (ja) 2023-04-18
KR102598666B1 (ko) 2023-11-07
US12419895B1 (en) 2025-09-23
AU2015346196B2 (en) 2019-01-31
AU2019202906A1 (en) 2019-05-16
JP7645913B2 (ja) 2025-03-14
EA201791067A1 (ru) 2017-11-30
NZ768958A (en) 2021-07-30
CN107106500A (zh) 2017-08-29
JP6709226B2 (ja) 2020-06-10
IL252111B (en) 2021-09-30
JP2017533972A (ja) 2017-11-16
JP2021193148A (ja) 2021-12-23
MX2021003982A (es) 2022-06-09
US10058557B2 (en) 2018-08-28
HUE050895T2 (hu) 2021-01-28
US12178823B1 (en) 2024-12-31
EA036103B1 (ru) 2020-09-29
MY187610A (en) 2021-10-04
MX393030B (es) 2025-03-24
AU2015346196A1 (en) 2017-06-29
CA3210794A1 (en) 2016-05-19
US20240423996A1 (en) 2024-12-26
ES2806977T3 (es) 2021-02-19
US20250288593A1 (en) 2025-09-18
WO2016077629A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
US12109216B2 (en) Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
JP2008510835A (ja) カリウムａｔｐチャンネル開放因子の製剤処方、及びその使用
US9757384B2 (en) Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
NZ731565B2 (en) Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
HK1243954B (en) Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Legal Events

Date Code Title Description
PB01 Publication